Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD
patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin
(DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in
vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro
platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The
investigators designed a prospective study to evaluate the effect of desmopressin on platelet
function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who
were taking antiplatelet drugs.